Use of Disease-Modifying Therapies in Patients With Late-Onset Multiple Sclerosis [0.03%]
延发多发性硬化症患者中使用疾病修正疗法的情况
Camille Robin,Fabien Rollot,Mathilde Lefort et al.
Camille Robin et al.
Background and objectives: The therapeutic strategy in patients with late-onset MS (LOMS) remains poorly defined. In this study, we aimed to evaluate both clinical and MRI outcomes between 2 cohorts of patients with relap...
Validation of the Seizure-Related Impact Assessment Scale: A Novel Patient-Reported Outcome Measure for Epilepsy [0.03%]
癫痫新型患者报告结果测量方法“与癫痫发作相关的评估量表”的验证研究
Emma Foster,Alison Conquest,Chris Ewart et al.
Emma Foster et al.
Background and objectives: There is a clear need in epilepsy clinical trials and practice for a measure that captures the trade-off between seizure and treatment-related adverse effects, which is reliable over time and ac...
Georgette Dib,Nicholas E Johnson
Georgette Dib
Teaching Video NeuroImage: Crossed Vertical Gaze Paresis: A Sign of a Supranuclear Lesion [0.03%]
交叉垂直性凝视麻痹：顶核病变的体征
Sofia Mônaco Gama,Pedro Fraiman,Gabriel Lopes da Silva et al.
Sofia Mônaco Gama et al.
Association of Medication Use and 8-Year Mortality Risk in Patients With Parkinson Disease: Drug-Wide Trial Emulation [0.03%]
药物使用与帕金森病患者8年死亡风险的关系：多药试验模拟研究
Julia A Tuominen,Trond Riise,Julia Romanowska et al.
Julia A Tuominen et al.
Background and objectives: There are currently no treatments that can halt or slow the progression of Parkinson disease (PD). The aim of this study was to identify new drug repurposing candidates for PD among existing pre...
Observational Study
Neurology. 2025 Aug 12;105(3):e213783. DOI:10.1212/WNL.0000000000213783 2025
Carlo Colosimo,Luca Marsili
Carlo Colosimo
Kevin Akeret,Luis Padevit,Guido Reifenberger et al.
Kevin Akeret et al.
Objectives: H3 G34-mutant diffuse hemispheric gliomas are rare, aggressive primary brain tumors predominantly affecting young patients. We investigated the prognostic value of anatomic staging (AS)-a system previously val...
What Physiological Features May Contribute to Purkinje Cell Vulnerability in Cerebellar Ataxias? [0.03%]
可能造成小脑共济失调患者浦肯野细胞易损性的生理特征有哪些？
Eduardo Benarroch
Eduardo Benarroch
Author Response: Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM [0.03%]
胎儿在宫内暴露于抗癫痫药物后的致畸性、围产期和神经发育结局：美国神经学学会(AAN)、美国癫痫学会(AES)和母胎医学学会(SMFM)的实践指南作者回复
Mark Robert Keezer,Maryam Oskoui,Alison M Pack
Mark Robert Keezer
Reader Response: Teratogenesis, Perinatal, and Neurodevelopmental Outcomes After In Utero Exposure to Antiseizure Medication: Practice Guideline From the AAN, AES, and SMFM [0.03%]
读者来信：抗癫痫药宫内暴露后的致畸性、围产期和神经发育结局：美国神经病学学会（AAN）、美国癫痫学会（AES）及美国母胎医学会（SMFM）实践指南
Marte-Helene Bjørk,Helga Zoega,Jakob Christensen
Marte-Helene Bjørk